These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8375268)

  • 1. Effect of a sulfonylurea (gliclazide) treatment on insulin sensitivity and glucose-mediated glucose disposal in patients with non-insulin-dependent diabetes mellitus (NIDDM).
    Wajchenberg BL; Santomauro AT; Porrelli RN
    Diabetes Res Clin Pract; 1993 May; 20(2):147-54. PubMed ID: 8375268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unchanged gene expression of glycogen synthase in muscle from patients with NIDDM following sulphonylurea-induced improvement of glycaemic control.
    Vestergaard H; Lund S; Bjørbaek C; Pedersen O
    Diabetologia; 1995 Oct; 38(10):1230-8. PubMed ID: 8690177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 6 months' gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial CSII-induced normoglycemia.
    Della Casa L; del Rio G; Glaser B; Cerasi E
    Diabetes Res Clin Pract; 1991; 14 Suppl 2():S69-78. PubMed ID: 1794269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of beta-cell function after long-term treatment with either insulin, insulin plus gliclazide or gliclazide in neonatal streptozotocin-induced non-insulin-dependent diabetic rats.
    Kawai K; Suzuki S; Murayama Y; Watanabe Y; Yamashita K
    Diabetes Res Clin Pract; 1991 Jul; 12(3):163-72. PubMed ID: 1832376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide.
    Wu CZ; Pei D; Hsieh AT; Wang K; Lin JD; Lee LH; Chu YM; Hsiao FC; Pei C; Hsia TL
    Arch Pharm Res; 2010 Mar; 33(3):411-6. PubMed ID: 20361306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of gliclazide on non-insulin dependent diabetes mellitus.
    Wajchenberg BJ; Santomaruo AT; Cherem JJ; Malerbi DA; Giurno Filho A; Lerario AC; Giannella Neto D
    Adv Exp Med Biol; 1988; 246():313-9. PubMed ID: 3074661
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of 6-month gliclazide treatment on insulin release and sensitivity to endogenous insulin in NIDDM: role of initial continuous subcutaneous insulin infusion-induced normoglycemia.
    Della Casa L; del Rio G; Glaser B; Cerasi E
    Am J Med; 1991 Jun; 90(6A):37S-45S. PubMed ID: 1872303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
    Rachman J; Levy JC; Barrow BA; Manley SE; Turner RC
    Diabetes; 1997 Oct; 46(10):1557-62. PubMed ID: 9313749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Fasting Hyperglycaemia Study: III. Randomized controlled trial of sulfonylurea therapy in subjects with increased but not diabetic fasting plasma glucose.
    Karunakaran S; Hammersley MS; Morris RJ; Turner RC; Holman RR
    Metabolism; 1997 Dec; 46(12 Suppl 1):56-60. PubMed ID: 9439561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy.
    Hosker JP; Rudenski AS; Burnett MA; Matthews DR; Turner RC
    Metabolism; 1989 Aug; 38(8):767-72. PubMed ID: 2668699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short- and long-term gliclazide effects on pancreatic islet cell function and hepatic insulin extraction in non-insulin-dependent diabetes mellitus.
    Wajchenberg BL; Santomauro AT; Giannella-Neto D; Borghi VC; Porrelli RN
    Diabetes Res Clin Pract; 1992 Aug; 17(2):89-97. PubMed ID: 1425152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of newly diagnosed non-insulin-dependent diabetes mellitus in the primary care setting: effects of 2 years of gliclazide treatment--the Diadem Study.
    Cathelineau G; de Champvallins M; Bouallouche A; Lesobre B
    Metabolism; 1997 Dec; 46(12 Suppl 1):31-4. PubMed ID: 9439556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of norepinephrine on insulin secretion and glucose effectiveness in non-insulin-dependent diabetes.
    Walters JM; Ward GM; Barton J; Arackal R; Boston RC; Best JD; Alford FP
    Metabolism; 1997 Dec; 46(12):1448-53. PubMed ID: 9439541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfonylurea therapy improves glucose disposal without changing skeletal muscle GLUT4 levels in noninsulin-dependent diabetes mellitus subjects: a longitudinal study.
    Vestergaard H; Weinreb JE; Rosen AS; Bjørbaek C; Hansen L; Pedersen O; Kahn BB
    J Clin Endocrinol Metab; 1995 Jan; 80(1):270-5. PubMed ID: 7829624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of sulphonylurea therapy on skeletal muscle glycogen synthase activity and insulin secretion in newly presenting type 2 (non-insulin-dependent) diabetic patients.
    Johnson AB; Argyraki M; Thow JC; Jones IR; Broughton D; Miller M; Taylor R
    Diabet Med; 1991 Apr; 8(3):243-53. PubMed ID: 1828740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased glucose effectiveness but not insulin resistance in glucose-tolerant offspring of Japanese non-insulin-dependent diabetic patients: a minimal-model analysis.
    Doi K; Taniguchi A; Nakai Y; Kawamura H; Higaki Y; Yokoi H; Tanaka H; Fujitani J; Suzuki M; Tokuyama K; Sakai M; Fukushima M
    Metabolism; 1997 Aug; 46(8):880-3. PubMed ID: 9258268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenic mechanism of type 2 diabetes in Ghanaians--the importance of beta cell secretion, insulin sensitivity and glucose effectiveness.
    Amoah AG; Owusu SK; Schuster DP; Osei K
    S Afr Med J; 2002 May; 92(5):377-84. PubMed ID: 12108171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of middle-term gliclazide treatment on insulin secretion in non-insulin dependent diabetics.
    Brogard JM; Pinget M; Dorner M
    Curr Med Res Opin; 1984; 9(1):56-63. PubMed ID: 6373160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic factors responsible for glucose intolerance in patients with NIDDM.
    Taniguchi A; Nakai Y; Fukushima M; Kawamura H; Imura H; Nagata I; Tokuyama K
    Diabetes; 1992 Dec; 41(12):1540-6. PubMed ID: 1446794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.